<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65257">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256345</url>
  </required_header>
  <id_info>
    <org_study_id>01340</org_study_id>
    <nct_id>NCT02256345</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be performed to determine the safety, tolerability, and dose-response to
      inorganic nitrate on exercise capacity in HFpEF. There are two primary goals for this study:

        1. Determine the population-specific pharmacokinetics and dose of KNO3 that can be safely
           given to subjects with HFpEF.

        2. Determine if there is a dose-response effect of nitrate supplementation on exercise
           capacity, evidenced by peak oxygen consumption (peak VO2), and physiologic adaptations
           to exercise.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak VO2 from baseline to the end of 1 week of administration for each dose</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vasodilatory reserve for each dose</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mitochondrial oxidative capacity for each dose</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aortic augmentation index</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diastolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>KNO3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>KNO3 will be given at a dose of 12 mmol for the first week, escalating to 18 mmol for the second week if well tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>KCl will be used as a placebo and will be given as 12 mmol for the first week, increasing to 18 mmol for the second week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Nitrate</intervention_name>
    <arm_group_label>KNO3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KCl</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>KCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. NYHA Class II-III symptoms.

          2. LV EF &gt; 50%.

          3. Stable medical therapy for at least 1 month.

          4. Evidence of significant diastolic dysfunction, meeting the European Society of
             Echocardiography criteria for HFpEF.

        Exclusion Criteria

          1. Any rhythm other than sinus with native conduction.

          2. Inability to exercise.

          3. Moderate or greater valvular disease.

          4. Hypertrophic, infiltrative, or inflammatory cardiomyopathy.

          5. Pericardial disease.

          6. Current angina.

          7. Acute coronary syndrome or coronary intervention within the past 2 months.

          8. Primary pulmonary arteriopathy.

          9. Clinically significant lung disease.

         10. Ischemia on stress testing without subsequent revascularization.

         11. Treatment with phosphodiesterase inhibitors that cannot be withheld.

         12. Treatment with organic nitrates or allopurinol.

         13. Significant liver disease impacting synthetic function or volume control.

         14. Poor echocardiographic windows.

         15. eGFR &lt; 30 mL/min/m2 or Cr &gt;2.5.

         16. Current smoking.

         17. Alcohol dependency.

         18. History of Barret's esophagus.

         19. G6PD deficiency

         20. Methemoglobinemia - baseline methemoglobin level &gt;3% prior to any study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>September 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
